In the present investigation two different approaches were attempted to develop colon targeted tablet of Naproxen for effective and safe therapy of inflammatory bowel diseases. In conclusion, the tablets F5 released only 1.96% of drug in the physiological environment of stomach and small intestine and released more than 97% of the drug in the colon. The presence of eudragit s 100 in the coat reduces the initial premature drug release in the upper part of GIT and ensures complete release of drug in the colon due to increased susceptibility of HPMC to degradation by bacterial enzymes present in dissolution fluids. Based on these results, the compression coated tablets F5 is most likely to provide targeted delivery of naproxen to colon. The prepared formulation was evaluated using various standard tests, and from the results it was concluded that the coating combination of both polymer, that is, HPMC and Eudragit S-100, was successful in preventing the drug release in the upper part of gastrointestinal tract. The in vitro drug release studies and SEM analysis demonstrated that the optimized formulation proved to be a promising drug delivery for colon targeting.
